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MaBACKGROUND Patients with ischemic left ventricular dysfunction have higher operative risk with coronary artery
bypass graft surgery (CABG). However, those whose early risk is surpassed by subsequent survival beneﬁt have not
been identiﬁed.
OBJECTIVES This study sought to examine the impact of anatomic variables associated with poor prognosis on the
effect of CABG in ischemic cardiomyopathy.
METHODS All 1,212 patients in the STICH (Surgical Treatment of IsChemic Heart failure) surgical revascularization trial
were included. Patients had coronary artery disease (CAD) and ejection fraction (EF) of #35% and were randomized to
receive CABG plus medical therapy or optimal medical therapy (OMT) alone. This study focused on 3 prognostic factors:
presence of 3-vessel CAD, EF below themedian (27%), and end-systolic volume index (ESVI) above themedian (79ml/m2).
Patients were categorized as having 0 to 1 or 2 to 3 of these factors.
RESULTS Patients with 2 to 3 prognostic factors (n ¼ 636) had reduced mortality with CABG compared with those who
received OMT (hazard ratio [HR]: 0.71; 95% conﬁdence interval [CI]: 0.56 to 0.89; p ¼ 0.004); CABG had no such effect
in patients with 0 to 1 factor (HR: 1.08; 95% CI: 0.81 to 1.44; p ¼ 0.591). There was a signiﬁcant interaction between the
number of factors and the effect of CABG on mortality (p ¼ 0.022). Although 30-day risk with CABG was higher, a net
beneﬁcial effect of CABG relative to OMT was observed at >2 years in patients with 2 to 3 factors (HR: 0.53; 95% CI: 0.37
to 0.75; p<0.001) but not in those with 0 to 1 factor (HR: 0.88; 95% CI: 0.59 to 1.31; p ¼ 0.535).
CONCLUSIONS Patients with more advanced ischemic cardiomyopathy receive greater beneﬁt from CABG. This sup-
ports the indication for surgical revascularization in patients with more extensive CAD and worse myocardial dysfunction
and remodeling. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
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554U nlike any other form of left ventric-ular (LV) dysfunction, patientswith ischemic cardiomyopathy
have the potential to improve their prognosis
with revascularization. Recent randomized
controlled trials have shown that revas-
cularization with coronary artery bypass
graft (CABG) surgery is superior to that with
percutaneous coronary interventions (PCI)
in patients with multivessel coronary artery
disease (CAD) (1,2). However, the decision
to pursue CABG is usually difﬁcult in is-
chemic cardiomyopathy patients, particu-
larly because the presence and severity of
LV dysfunction impose a higher operativerisk (3,4). The STICH (Surgical Treatment of IsChemic
Heart failure) trial recently tested the hypothesis that
surgical revascularization with CABG improves the
survival of patients with ischemic LV dysfunction
compared with that of patients receiving optimal
medical therapy (OMT) without revascularization
(5). During a median follow-up of 56 months, STICH
demonstrated a trend toward better survival with
CABG that did not reach statistical signiﬁcance
(p ¼ 0.12) (5). Importantly, the treatment effect of
CABG over medical therapy occurred in a clear time-
dependent pattern, with an early (within 30 days)
increased hazard related to the operative mortality
and a late ($2 years) survival beneﬁt (Fig. 1).SEE PAGE 562Several previous studies have shown that among
patients with CAD, the number of vessels with an-
giographically detected stenoses, the LV ejection
fraction (EF), and the LV end-systolic volume index
(ESVI) are associated with prognosis (3,4,6–12). How-
ever, how these variables should be incorporated into
the decision regarding revascularization in patients
with ischemic cardiomyopathy is unclear. Hazard ra-
tio (HR) analyses of pre-determined subgroups in
STICH did not identify any variable with a statistically
signiﬁcant interaction with treatment allocation (see
Fig. 3 Velazquez et al. [5]) and the lack of statistical
signiﬁcance for the primary endpoint in STICH has
led to the concept that the indication for surgical
revascularization in ischemic cardiomyopathy can be
safely deferred until medical therapy fails or thel Institutes of Health (grants: U01HL69015 and U01HL69013). Dr.
ticals. All other authors have reported that they have no rel
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received January 22, 2014; revised manuscript received April 17,patient becomes unstable (13,14). However, previous
analyses did not address whether the time-dependent
survival relationship between the 2 treatment arms
varies according to baseline risk.
Accordingly, the purpose of this study was to
examine the impact of key anatomic variables used in
routine clinical practice and known to be associated
with prognosis on the time-dependent hazard of
CABG relative to that of OMT in patients enrolled
in the surgical revascularization hypothesis of the
STICH trial. We hypothesized that this analysis could
lead to the recognition of a group of patients whose
early surgical risk is rapidly surpassed by subsequent
survival beneﬁt and in whom, therefore, the indica-
tion for CABG is more clearly supported.
METHODS
STUDY POPULATION. STICH was a prospective,
multicenter, nonblinded, randomized trial sponsored
by the National Heart, Lung, and Blood Institute
(NHLBI) that recruited 2,136 patients with CAD and
LV EF of #35% between 2002 and 2007. The trial
was designed to address 2 primary hypotheses: 1)
that CABG combined with OMT improved survival
compared with OMT alone (surgical revascularization
hypothesis); and 2) that surgical ventricular recon-
struction added to CABG improved survival free of
cardiovascular hospitalization compared with CABG
alone in patients with signiﬁcant anterior wall akine-
sis (surgical ventricular reconstruction hypothesis).
The trial design and results of the 2 primary hypoth-
eses have been reported previously (5,15,16). For the
purpose of this study, only the 1,212 patients included
in the surgical revascularization arm were considered.
All patients had angiographic documentation of
CAD that favored a diagnosis of CABG and EF of
#35%. Patients with left main coronary stenosis
of >50%, cardiogenic shock, myocardial infarction
within 3 previous months, or who demonstrated a
need for aortic valve surgery were excluded. Patients
were randomly assigned to receive CABG with medi-
cal therapy or medical therapy alone. PCI was not
considered among the revascularization strategies in
the STICH protocol. According to the original design
of the trial (15), PCI during follow-up was regarded
as downstream medical care associated with eitherPrabhakaran has received honoraria from Torrent
ationships relevant to the contents of this paper
alentin Fuster.
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2014, accepted April 21, 2014.
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FIGURE 1 Time-Varying Hazard Ratios for All-Cause Mortality in Patients Randomized to Receive CABG or OMT in the STICH Trial
CABG ¼ coronary artery bypass graft surgery; MED ¼ medical therapy alone; OMT ¼ optimal medical therapy; STICH ¼ Surgical Treatment of
IsChemic Heart failure.
TABLE 1 Comparison of Baseline Characteristics of Patients With
Different Numbers of Prognostic Factors According to 3-Vessel Disease,
Low LVEF, and High ESVI
Variable
Patients With 0–1
Prognostic Factor
(n ¼ 576)
Patients With 2–3
Prognostic Factors
(n ¼ 636) p Value
Age, yrs 60  9 60  9 0.961
Females 90 (16) 58 (9) <0.001
White patients, % 390 (68) 437 (69) 0.708
Body mass index, kg/m2 27  5 27  5 0.683
History of myocardial
infarction
436 (76) 498 (78) 0.281
Atrial ﬂutter or ﬁbrillation 58 (10) 95 (15) 0.011
Previous CABG 10 (2) 26 (4) 0.016
Previous PCI 68 (12) 88 (14) 0.292
Advanced angina* 33 (6) 25 (4) 0.143
Advanced heart failure† 179 (31) 268 (42) <0.001
3-vessel CAD 289 (50) 445 (70) <0.001
Moderate or severe mitral
regurgitation
83 (14) 137 (22) 0.001
LV EF, % 34  7 23  5 NA
ESVI, ml/m2 61  16 104  30 NA
EDVI, ml/m2 92  24 139  37 NA
Patients randomized
to CABG
274 (48) 336 (53) 0.067
Values are mean  SD or n (%). *Canadian Cardiac Society class III or IV. †New York Heart
Association functional class III or IV.
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; EDVI ¼ end-diastolic
volume index; EF ¼ ejection fraction; ESVI ¼ end-systolic volume index; LV ¼ left ventricle/
ventricular; LVEF ¼ left ventricular ejection fraction; NA ¼ not applicable; PCI ¼ percutaneous
coronary intervention.
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555of the treatment strategies, and PCI was performed
as a subsequent procedure in only 37 of the 602 pa-
tients (6%) randomized to medical therapy alone
and in 26 of the 610 patients (4%) randomized to
CABG (p ¼ NS). The NHLBI and ethics committee at
each recruiting institution approved the study pro-
tocol. All patients provided written informed consent
for participation in the trial.
For the purpose of this study, attention was
focused on 3 variables known to be prognostically
important: 1) presence of 3-vessel CAD (deﬁned as
$50% stenosis); 2) baseline LV EF; and 3) baseline LV
ESVI. These variables were selected prospectively for
the purpose of this analysis on the basis of their
known prognostic signiﬁcance. Assessment of coro-
nary anatomy was made by the investigators at each
recruiting center and relayed to the Data Coordi-
nating Center at Duke University, using speciﬁcally
designed data collection forms. LV EF and LV ESVI
were measured by core laboratories independently
funded by NHLBI and blinded to all clinical and
outcome information. As previously published, the
best available method (on the basis of study quality
using a pre-determined hierarchical algorithm) was
used for LV EF and LV ESVI measurements (17).
Patients were divided in a binary fashion according to
the presence or absence of 3-vessel disease, LV EF
below or above the median value, and LV ESVI below
or above the median value. In addition, each patient
was categorized by the number of prognostic factors
deﬁned by these variables, namely: 1) presence of
3-vessel CAD; 2) LV EF below the median value; and 3)
LV ESVI above the median value. The presence of
3-vessel CAD was selected on the basis of the resultsfrom the CASS (Coronary Artery Surgery Study) trial
showing that this variable identiﬁes a population of
patients that may preferentially beneﬁt from CABG
(18). The thresholds for EF and ESVI were selected
post-hoc on the basis of the median values of the
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Comparison Hazard Ratio 95% CI P–value
2–3 Factors : 0–1 Factors 1.64 1.33, 2.02 < 0.001
0.38
0.24
Years Following RandomizationPatients at Risk:
0–1
2–3
Factors
Factors
576
636
523
541
490
483
457
437
Ca
rd
io
va
sc
ul
ar
 M
or
ta
lit
y 
Ra
te
338 172
156
86
85314
0-1 Factors (N=576)
2-3 Factors (N=636)
B
1.00
0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0
Comparison Hazard Ratio 95% CI P–value
2–3 Factors : 0–1 Factors 1.49 1.24, 1.80 < 0.001
0.44
0.30
Years Following Randomization
Patients at Risk:
0–1 Factors
2–3 Factors
576
636
523
541
490
483
457
437
 M
or
ta
lit
y 
Ra
te
338 172
156
86
85314
0-1 Factors (N=576)
2-3 Factors (N=636)
A
FIGURE 2 Kaplan-Meier Estimates of Mortality Rates
Kaplan-Meier estimates are shown for all-cause (A) and cardiovascular (B) mortality rates.
In each panel, study patients are divided according to the presence of 0 to 1 or 2 to 3
prognostic factors, regardless of treatment allocation.
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556STICH population; no multiple views or comparisons
with other thresholds were performed. For the pur-
pose of data analysis, patients were grouped into
those having 0 to 1 and those having 2 to 3 prognostic
factors.
FOLLOW-UP AND OUTCOMES. After enrollment, pa-
tients were followed every 4 months for the ﬁrst
year and every 6 months thereafter. Adherence
to guideline-directed medical therapy was high
throughout the study period, without signiﬁcant dif-
ferences between the treatment groups (5). As forthe primary STICH trial analysis, the primary out-
come was death from any cause, and the secondary
endpoint was death from cardiovascular causes.
Deﬁnitions of the trial endpoints have been previ-
ously reported (5). An independent clinical events
committee adjudicated all endpoints. Median follow-
up was 56 months (maximum, 8.3 years).
STATISTICAL ANALYSES. Demographic and baseline
variables were summarized by using means and
standard deviations for continuous variables and by
number (n) and percentage (%) for categorical vari-
ables. Comparisons for continuous and ordinal vari-
ables between patient groups were performed with
the Wilcoxon rank-sum test. The chi-square test or
Fisher exact test was used to compare categorical
variables.
Event rate estimates in each patient group
were calculated using the Kaplan-Meier method
and presented graphically (19). The signiﬁcance of
differences in mortality between patient groups was
assessed using the log-rank test (20). Relative risks,
expressed as HRs with associated 95% CIs, were
derived using the Cox regression model (21). The
interaction of prognostic factors and randomized
treatment with respect to mortality was also assessed
using the Cox model.
To examine the time-dependent nature of the
randomized treatment effect, time-varying HRs
and 95% CIs comparing CABG with medical therapy
were calculated for discrete time periods after
randomization (i.e., #30 days; 31 to 365 days; 366
days to 2 years; and >2 years). These time points
were selected prospectively for the purpose of
this study. This analysis also was performed sepa-
rately by patient groups (e.g., patients with 0 to 1
prognostic factor and patients with 2 to 3 prognostic
factors).
All mortality comparisons of the randomized treat-
ment arms were performed according to intention-to-
treat principle (as randomized). Secondary analyses
included comparisons by treatment received (e.g.,
CABG or medical therapy, regardless of randomiza-
tion), and according to protocol (i.e., excluding the
patients who crossed over to the other treatment arm).
All 462deaths (38.1%of theSTICHpopulation) reported
at the time of database closure were included in the
analysis.
RESULTS
STUDY POPULATION. Of the 1,212 patients included
in the STICH revascularization hypothesis trial, 734
had 3-vessel CAD. The median LV EF was 26.7%, and
the median ESVI was 78.6 ml/m2. There were 576
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FIGURE 3 Kaplan-Meier Estimates of All-Cause Mortality Rates
by Number of Prognostic Factors
Kaplan-Meier rate estimates are shown for all-cause mortality among patients
with 2 to 3 (top panel) and 0 to 1 (bottom panel) prognostic factors. In each
panel, study patients are divided according to the treatment arm (CABG or
OMT) to which they were randomized. Abbreviations as in Figure 1.
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557patients with 0 to 1 prognostic factor and 636 patients
with 2 to 3 prognostic factors, as deﬁned above.
Table 1 shows the distribution of baseline character-
istics in the patient groups deﬁned according to
the number of prognostic variables. As expected,
compared with patients with 0 to 1 prognostic factor,
those with 2 to 3 factors had a greater prevalence
of characteristics associated with poor prognosis,
including greater proportion of atrial ﬂutter or
ﬁbrillation, previous CABG, moderate or severe mitral
regurgitation, and more common presentation of
advanced heart failure. Accordingly, patients with 2
to 3 prognostic factors had signiﬁcantly higher overall
mortality and higher rates of cardiovascular mor-
tality than those with 0 to 1 prognostic factor, when
treatment allocation was not considered (Fig. 2).
EFFECT OF SURGICAL REVASCULARIZATION ON
SURVIVAL ACCORDING TO KEY ANATOMIC VARIABLES.
Patients with 3-vessel CAD received a signiﬁcant
beneﬁt with CABG compared with those receiving
medical therapy alone in terms of overall mortality
(p ¼ 0.046) and cardiovascular deaths (p ¼ 0.030). In
contrast, no such effect was observed among patients
without 3-vessel CAD (p ¼ 0.906 and p ¼ 0.554 for
overall and cardiovascular mortality, respectively)
(Online Figs. 1 and 2). Similarly, patients with LV EF
below the median value had reduced overall mortal-
ity (p ¼ 0.021) and cardiovascular mortality (p ¼
0.043) with CABG compared with patients receiving
medical therapy, an effect not found among patients
with EF above the median value (p ¼ 0.970 and
p ¼ 0.288 for overall and cardiovascular mortality,
respectively) (Online Figs. 3 and 4). Patients with LV
ESVI higher than the median value had a marginal
reduction in overall mortality (p ¼ 0.055) with CABG
compared with those receiving medical therapy and
no signiﬁcant beneﬁt in terms of cardiovascular mor-
tality (p ¼ 0.177), whereas no signiﬁcant differences
were noted between the 2 treatment arms among
patients with ESVI below the median (p ¼ 0.596 and
p ¼ 0.064 for overall and cardiovascular mortality,
respectively) (Online Figs. 5 and 6). Finally, when
patients with 2 to 3 prognostic factors were analyzed
as a group, there was a highly signiﬁcant mortality
reduction with CABG compared with that observed
with medical therapy alone (HR: 0.71; CI: 0.56 to 0.89;
p ¼ 0.004); no such therapeutic effect of CABG was
found among patients with 0 to 1 prognostic factor
(HR: 1.08; CI: 0.81 to 1.44; p ¼ 0.591). A statistically
signiﬁcant interaction (p ¼ 0.022) was observed be-
tween the number of prognostic factors and the
treatment effect of CABG on mortality (Fig. 3). Anal-
ysis of the Kaplan-Meier mortality rates according totreatment allocation among patients with 2 to 3 prog-
nostic factors revealed that the curves crossed (indi-
cating the elimination of the higher surgical risk) at
approximately 6 to 15 months after randomization
(Fig. 3, top panel). This was also true for patients
with only 1 prognostic factor (Online Figs. 1, 3, and 5).
Patients with 2 to 3 factors also had reduced cardio-
vascular mortality with CABG compared with those
receiving medical therapy (HR: 0.72; CI: 0.56 to 0.94;
p ¼ 0.014), with no such effect observed among
patients with 0 to 1 factor (HR: 0.89; CI: 0.64 to 1.25;
p ¼ 0.502).
Of note, among patients randomized to medical
therapy alone, there was a signiﬁcantly higher mor-
tality in patients with 2 to 3 prognostic factors than in
those with 0 to 1 factor (p < 0.001). However, such
a difference was not observed among patients ran-
domized to CABG (p ¼ 0.190), hence indicating that
the treatment effect of surgical revascularization
markedly blunted the higher mortality risk conveyed
by the presence of anatomic ﬁndings associated
with poor prognosis (Fig. 4).
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FIGURE 4 Kaplan-Meier Estimates of All-Cause Mortality by Treatment Arm
Kaplan-Meier estimates are shown for all-cause mortality rates among patients random-
ized to OMT (top panel) or CABG (bottom panel). In each panel, study patients are divided
according to the presence of 0 to 1 or 2 to 3 prognostic factors. Abbreviations as in Figure 1.
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558TIME-DEPENDENT MORTALITY HAZARD OF CABG
VERSUS MEDICAL THERAPY ACCORDING TO KEY
ANATOMIC VARIABLES. Patients with 3-vessel CAD,
those with LV EF below the median, and those
with LV ESVI above the median had a clear time-
dependent overall and cardiovascular mortality haz-
ard with surgical revascularization, with an early
higher risk (within 30 days) with CABG and a
clear beneﬁt at $2 years (Online Figs. 7 to 12). This
time-dependent hazard was different among the
subgroups of patients without these anatomiccharacteristics, in that their mortality beneﬁt with
CABG was not statistically signiﬁcant at $2 years
(except for reduced cardiovascular mortality in pa-
tients without 3-vessel CAD and in those with LV ESVI
above the median) (Online Figs. 8 and 12).
Of note, when the anatomic characteristics were
combined, patients with 2 to 3 prognostic factors
showed a trend toward higher overall mortality
(p ¼ 0.087) and statistically signiﬁcant higher car-
diovascular mortality (p ¼ 0.048) with CABG within
30 days and a markedly signiﬁcant beneﬁt of CABG
at $2 years in terms of overall mortality (p<0.001)
and cardiovascular deaths (p ¼ 0.003) than those
randomized to medical therapy alone. The overall
HR was 0.71 (95% CI: 0.56 to 0.89; p ¼ 0.004) for all-
cause mortality and 0.72 (95% CI: 0.56 to 0.94;
p ¼ 0.014) for cardiovascular deaths. In contrast,
patients with 0 to 1 prognostic factor had a signiﬁ-
cantly higher early mortality hazard with CABG than
those receiving medical therapy alone (p ¼ 0.047 for
both overall and cardiovascular mortality), without
survival beneﬁt at any time point (overall HR: 1.08;
95% CI: 0.81 to 1.44; p ¼ 0.591 for all-cause mortality
and 0.89; 95% CI: 0.64 to 1.25; p ¼ 0.502 for cardio-
vascular deaths) (Fig. 5). In patients randomized
to CABG, the early mortality (within 30 days of ran-
domization) among patients with 2 to 3 prognostic
factors (3.57%) was similar to that in patients with
0 to 1 prognostic factor (3.65%).
Analyses of the data according to treatment
received (e.g., CABG or medical therapy regardless
of randomization) and protocol (i.e., excluding the
patients who crossed over to the other treatment
arm) showed results similar to those of the primary
intention-to-treat analysis (Online Figs. 13 and 14).
DISCUSSION
The decision of whether to proceed with surgical
revascularization in a patient with ischemic cardio-
myopathy is an increasingly common one, given
the rising prevalence of this condition (22). Unfor-
tunately, it is also a difﬁcult one because of the
complexity and variability of the clinical presen-
tations and, until recently, because of the paucity of
data from randomized clinical trials. The recently
completed STICH trial showed a trend (p ¼ 0.12)
toward better overall survival with CABG than medi-
cal therapy alone and a statistically signiﬁcant ben-
eﬁt in the secondary endpoints of cardiovascular
mortality and death from any cause plus cardiac
hospitalization (5). As expected, on the basis of clin-
ical experience, the mortality curves for the 2 treat-
ment arms crossed during the follow-up period due
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FIGURE 5 Time-Dependent Hazard Ratios for All-Cause Mortality by Treatment Arm
Time-dependent hazard ratios are shown for all-cause (top panel) and cardiovascular
(bottom panel) mortality for CABG versus OMT. Study patients are divided according to
the presence of 2 to 3 (upper part of each panel) or 0 to 1 (lower part of each panel)
prognostic factors. CV ¼ cardiovascular; other abbreviations as in Figure 1.
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559to the increased early but decreased late mortality
observed with CABG. This increased early risk of
death with surgery partly negates the overall beneﬁt
of CABG and, most importantly, may be limited to
certain subgroups of patients. Identiﬁcation of those
patients whose early surgical risk is clearly offset
by the long-term beneﬁt of revascularization could
lead to the selection of a speciﬁc group of patients
in whom deferring surgery may not be the most
appropriate choice.
The results of this study demonstrate that patients
with more advanced forms of ischemic cardiomyop-
athy (as expressed by the presence of 3-vessel disease
and more severe LV systolic dysfunction and remod-
eling) are those who receive the greatest beneﬁt
from surgical revascularization. Thus, among the
1,212 patients enrolled in the STICH revascularization
hypothesis trial, those with $50% stenosis in all
3 major coronary arteries, LV EF below the median
value, and LV ESVI above the median value showed
a clear time-dependent beneﬁt of CABG compared
with those receiving medical therapy alone. This
resulted in an overall statistically signiﬁcant beneﬁt
of CABG over the entire follow-up period despite
the higher early (within 30 days) mortality with sur-
gery compared with that with medical therapy.
Importantly, as the number of prognostic factors
deﬁned by these variables increases, the time-
dependent pattern of the beneﬁt of CABG relative
to medical therapy (e.g., diminished early surgical
risk and enhanced late beneﬁt) becomes more
pronounced.
These ﬁndings have important clinical implications
for patients with ischemic cardiomyopathy that may
inﬂuence the paradigm used by clinicians for their
decision regarding surgical revascularization (Central
Illustration). Although more extensive CAD and
worse LV dysfunction and remodeling may be intui-
tively thought to be associated with increased oper-
ative mortality, instinctively leading to the avoidance
of CABG, our ﬁndings do not conﬁrm that view: the
early mortality with CABG in patients with 2 to 3
prognostic factors was similar to that observed among
patients with 0 to 1 prognostic factor. Instead, the
present study results indicate that those characteris-
tics are found among patients who derive the greatest
beneﬁt from revascularization and, hence, are those
in whom CABG may not be delayed. Patients with a
higher number of prognostic factors beneﬁt from
surgical revascularization because their early and late
mortality with medical therapy alone is extremely
high. Consequently, the risk of CABG in patients with
more advanced forms of ischemic cardiomyopathy
is counterbalanced by the even higher mortalityobserved with medical therapy alone. In fact, our
ﬁndings support the notion that surgical revasculari-
zation blunts the higher mortality conveyed by the
presence of anatomic prognostic factors when pa-
tients are treated with medical therapy alone. As a
result, the analysis favors the indication for surgical
revascularization in patients who present with worse
CAD and more severe LV dysfunction and remo-
deling. Importantly, although PCI may appear to be
an alternative for some patients, recent randomized
trials have demonstrated the superiority of surgical
revascularization in patients with extensive disease
or diabetes (1,2). Nevertheless, it must be acknowl-
edged that CABG in STICH was performed by ex-
perienced surgeons with a previously documented
CENTRAL ILLUSTRATION Schematic Representation of the Clinical Implications
of the Present Study Findings
The EF and ESVI thresholds (*) are the median values of the left ventricular (LV) function
variables in the present study and have not been validated prospectively in an independent
patient population. This algorithm should only be applied conceptually to support the
notion that among patients with ischemic LV systolic dysfunction, the beneﬁt of surgical
revascularization is greater when the disease process is more advanced (see text for more
detail). CAD ¼ coronary artery disease; EF ¼ ejection fraction; ESVI¼ end-systolic volume
index.
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560operative mortality rate of #5% in similar patients;
hence, these ﬁndings may not be applicable to centers
with a higher surgical death rate.
STUDY LIMITATIONS. First, these observations are
on the basis of a retrospective nonprespeciﬁed anal-
ysis of the STICH trial and therefore do not neces-
sarily have the same level of credibility as those that
can be derived from prospectively deﬁned subgroups
of patients entered into a clinical trial. Nonetheless,
the allocation to CABG or medical therapy alone was
prospectively decided by randomization. Accord-
ingly, the number of patients undergoing CABG was
approximately one-half in each of the subgroups,
ruling out any potential biased association between
allocation to surgical revascularization and presence
of 3-vessel CAD, lower EF, or higher ESVI. Second, the
STICH trial was designed with statistical power to
detect differences in overall survival with CABG over
that with medical therapy alone in all CAD patients
with EF #35%. Therefore, categorizing patients ac-
cording to those anatomic variables obviously resul-
ted in a reduced number of patients in each subgroup
with a consequently diminished statistical power.
Crossover of patients from 1 treatment arm to theother also may have affected the results of our
study, which was based on an intention-to-treat
analysis. The impact of crossovers in the STICH
trial has been carefully analyzed in a separate study
(23). Importantly, however, the “as treated” and “per
protocol” analyses (both of which considered cross-
over patients) showed results similar to those of the
primary intention-to-treat analysis. Finally, because
the median follow-up of the STICH trial was 56
months, we cannot establish whether the beneﬁt
of CABG observed after 2 years in certain subsets of
patients extends beyond this period of follow-up.
The STICH ES (STICH Extension Study) is presently
being conducted to conﬁrm the longer-term effects
of surgical revascularization in these patients.
It must be emphasized that the LV EF and LV
ESVI values used to separate patients into subgroups
were determined on the basis of the distribution of
these variables in this particular study population.
Because these thresholds have not been validated
prospectively in an independent patient population,
our ﬁndings should not be considered dogmatic pos-
tulates of speciﬁc values to be used when making
decisions for individual patients. Instead, these re-
sults should be applied conceptually to support the
notion that among patients with LV systolic failure
due to ischemic heart disease, the beneﬁt of surgical
revascularization is greater when the disease process
is more advanced.
Taken in conjunction with the neutral results of
the myocardial viability (24) and myocardial ischemia
(25) substudies, the present study results indicate
that compared with functional imaging, assessment
of the anatomical extent of the disease is a better
predictor of beneﬁt from CABG in patients with
ischemic cardiomyopathy. This concept is consistent
with that reported in a recent analysis by the
COURAGE trial investigators (26) in which the
anatomic burden was a more consistent predictor of
outcome than the assessment of the ischemic burden
in patients with EF of $30%.
CONCLUSIONS
Our ﬁndings support the indication for surgical
revascularization in patients with ischemic cardio-
myopathy who present with more extensive CAD and
worse myocardial dysfunction and remodeling.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Among
patients with left ventricular (LV) systolic failure due to
ischemic heart disease, the beneﬁt of surgical revascu-
larization is greater when the disease process is more
advanced.
COMPETENCY IN PATIENT CARE: Patients with
ischemic cardiomyopathy should be made aware that
assessment of the anatomical extent of the disease is
important to estimate the beneﬁt of coronary artery
bypass surgery (CABG) over medical therapy.
TRANSLATIONAL OUTLOOK 1: Because the median
follow-up of the STICH trial was 56 months, the beneﬁt
of CABG beyond this period of follow-up is uncertain. The
STICH Extension Study (STICHES) is presently being
conducted to conﬁrm the longer-term effects of surgical
revascularization in these patients.
TRANSLATIONAL OUTLOOK 2: Taken in conjunction
with the neutral results of the myocardial viability and
myocardial ischemia STICH substudies, it appears that,
compared to functional imaging, assessment of the
anatomical extent of the disease is a better predictor of
beneﬁt from CABG, a concept consistent with that reported
in a recent report from theCOURAGE trial. Hence, evaluation
of the added value of functional imaging to that provided by
anatomic assessment of the disease should be undertaken.
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